ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CNTA Centessa Pharmaceuticals PLC

11.04
-0.36 (-3.16%)
10 Aug 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Centessa Pharmaceuticals PLC NASDAQ:CNTA NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -0.36 -3.16% 11.04 11.08 11.67 11.61 10.95 11.42 332,516 01:00:00

CNTA SHAREHOLDER ALERT: Jakubowitz Law Reminds Centessa Shareholders of a Lead Plaintiff Deadline of November 28, 2022

14/10/2022 10:45am

PR Newswire (US)


Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart


From Aug 2022 to Aug 2024

Click Here for more Centessa Pharmaceuticals Charts.

NEW YORK, Oct. 14, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Centessa Pharmaceuticals plc (NASDAQ: CNTA).

To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/centessa-pharmaceuticals-loss-submission-form/?id=32618&from=4

This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Centessa American Depositary Shares pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about May 28, 2021; and/or (b) Centessa securities between May 28, 2021 and June 1, 2022.

Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until November 28, 2022 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, Centessa Pharmaceuticals plc issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company's product, lixivaptan, was less safe than defendants had represented; (ii) defendants overstated lixivaptan's clinical and commercial prospects; (iii) another Centessa product, ZF874, was less safe than defendants had represented; (iv) defendants overstated ZF874's clinical and commercial prospects while downplaying the drug's safety issues; and (v) as a result, documents issued in connection with Centessa's initial public offering and the Company's public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

Cision View original content:https://www.prnewswire.com/news-releases/cnta-shareholder-alert-jakubowitz-law-reminds-centessa-shareholders-of-a-lead-plaintiff-deadline-of-november-28-2022-301649238.html

SOURCE Jakubowitz Law

Copyright 2022 PR Newswire

1 Year Centessa Pharmaceuticals Chart

1 Year Centessa Pharmaceuticals Chart

1 Month Centessa Pharmaceuticals Chart

1 Month Centessa Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock